We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads
Product News

IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads

IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads
Product News

IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, and aTen Therapeutics Limited, a private biopharmaceutical company developing next-generation antibodies for the treatment of cancer, announced that they have entered into a strategic collaboration. Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen.

Dr John McCafferty, CEO and Founder of IONTAS, said: “The use of traditional in vivo technologies can work well to generate simple therapeutic antibodies, but with increasing requirements for specificity, function, developability, and affinity, these traditional approaches are not always appropriate. IONTAS will apply its technologies to overcome limitations of other platforms to generate therapeutic leads against pre-defined specification from aTen, to help its current pipeline progress.”

Prof Chris Wood, Chairman and Founder of aTen, commented: “IONTAS was selected because of its technological expertise and proven track record of delivering antibodies to all its partners. We value the extensive experience IONTAS can add to advancing aTen’s therapeutic programs in the fight against cancer.”
Advertisement